GILD

[Dividend Watcher]

(09-09-2015, 08:28 PM)Turvok Wrote: Anyone see this?
http://www.iflscience.com/health-and-med...-effective

I feel like this could definitely help out GILD. With the pull-back recently, one might be able to pick this up for under $100. Not the best dividend play, but potential growth

• The gay & bi population is estimated at around 3-4% of the U.S. population according to the last census. I would assume similar statistics throughout the world.
  
• Some (it could be argued that many, if not most, at-risk that can afford it) are already on maintenance or prophylaxis regimens.
  
• The majority of antiviral sales was comprised of Harvoni/Solvadi prescriptions.
  

I'm not sure this news will produce much more than a "blip on the radar" for sales.

This is not to say that GILD isn't worth due diligence and perhaps investing in if it meets your criteria. The have quite a few products in trial, one improved HIV treatment has just been given FDA approval recently, and some promising oncology treatments coming. In addition, they have a lot of cash available for acquisitions and research.

It wasn't that long ago when an HIV diagnosis was a death sentence. I lost my best friend from high school in the early days of the AIDS epidemic. It's too bad GILD didn't have its lifesaver "cocktails" on the market back then.